a(CHEBI:bupropion) decreases act(p(HBP:"alpha-4 beta-2 nAChR"))

PubMed:19126755

Finally, bupropion (16, 294, 433) and UCI-30002 (514) are examples of synthetic compounds that act as noncompetitive inhibitors of different nAChRs, including those made up of the subunits alpha7, alpha4beta2, or alpha3beta4. Both compounds effectively decrease nicotine self-administration in rats (280, 514). Bupropion is presently approved as an adjunct therapy for smoking cessation.

Related Edges 7

• a(CHEBI:bupropion) decreases act(p(HGNC:CHRNA7))
• a(CHEBI:bupropion) decreases act(p(HBP:"alpha-3 beta-4 nAChR"))
• a(CHEBI:bupropion) association path(MESH:"Smoking Cessation")
• a(MESH:"N-(1,2,3,4-tetrahydro-1-naphthyl)-4-nitroaniline") decreases act(p(HGNC:CHRNA7))
• a(MESH:"N-(1,2,3,4-tetrahydro-1-naphthyl)-4-nitroaniline") decreases act(p(HBP:"alpha-4 beta-2 nAChR"))
• a(MESH:"N-(1,2,3,4-tetrahydro-1-naphthyl)-4-nitroaniline") decreases act(p(HBP:"alpha-3 beta-4 nAChR"))
• path(MESH:"Smoking Cessation") association a(CHEBI:bupropion)

Text Location

Review

BEL Commons is developed and maintained in an academic capacity by Charles Tapley Hoyt and Daniel Domingo-Fernández at the Fraunhofer SCAI Department of Bioinformatics with support from the IMI project, AETIONOMY. It is built on top of PyBEL, an open source project. Please feel free to contact us here to give us feedback or report any issues. Also, see our Publishing Notes and Data Protection information.

If you find BEL Commons useful in your work, please consider citing: Hoyt, C. T., Domingo-Fernández, D., & Hofmann-Apitius, M. (2018). BEL Commons: an environment for exploration and analysis of networks encoded in Biological Expression Language. Database, 2018(3), 1–11.